Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer

Inclusion Criteria: * Advanced or metastatic pancreatic adenocarcinoma diagnosed by pathology; * Previously received a standard first-line chemotherapy regimen of pancreatic cancer * Age ≥ 18 and≤ 75 years old; * Expected survival ≥ 3 months; * ECOG score 0-1; * Child-Pugh score \< 8; * There is at least one measurable tumor lesion: the long diameter is ≥10 mm, and the short diameter of lymph nodes is ≥15 mm; * The results of liver and kidney function and blood routine examination within 1 week before enrollment meet the following conditions: Neutrophils (ANC) ≥ 1.5×109/L, platelets (PLT) ≥ 80×109/L, hemoglobin (HGB) ≥ 80g/L; Serum creatinine (Cr) ≤ 1.5 × upper limit of normal value; total bilirubin (TBIL) ≤ 2.5 × upper limit of normal value, Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) ≤2.5× upper limit of normal value; \- The patient voluntarily participated in this study and signed the informed consent form. Exclusion Criteria: * Received other immunotherapy previously(including immune checkpoint inhibitor PD-1/PDL1 and other immune checkpoint inhibitors) and/or anti-angiogenic drugs (including anti-VEGFR monoclonal antibody and anti-angiogenic small molecule kinase inhibitors) ; Known to be severely allergic to the drugs used in the study of tislelizumab and anlotinib; * Patients with obstructive jaundice who cannot reach TBIL ≤ 2.5 times the upper limit of normal value after surgical intervention; * Patients with biliary obstruction that may occur or worsen within 4 to 6 weeks; * Obvious blood coagulation disorder, active bleeding and bleeding tendency; * There is a history of other malignant tumors within 5 years (adequately treated skin basal cell carcinoma, cervical in situ); * Interstitial pneumonia or pulmonary fibrosis; * Uncontrollable pleural effusion or ascites; * Severe uncontrolled medical diseases, acute infections, recent history of myocardial infarction (within 3 months); * During pregnancy or breastfeeding, and those who refuse to take appropriate contraceptive measures during the test; * Patients judged by the investigator to be inappropriate to participate in this study.